Exploratory efficacy endpoints in the Community-Acquired Pneumonia Immunization Trial in Adults (CAPiTA)

Highlights • The 23 remaining exploratory endpoints of CAPiTA are reported. • PCV13 efficacy was 28.9–75.0% and was significant for 8 exploratory endpoints. • Significant efficacy included all confirmed pneumococcal CAP and IPD episodes. • VT serotype 1 and 7F was most common among PCV13 and placebo...

Full description

Saved in:
Bibliographic Details
Published in:Vaccine 2017-03, Vol.35 (9), p.1266-1272
Main Authors: Webber, Chris, Patton, Michael, Patterson, Scott, Schmoele-Thoma, Beate, Huijts, Susanne M, Bonten, Marc J.M
Format: Article
Language:English
Subjects:
Adult
Age
Aged
Aged, 80 and over
Allergy and Immunology
Antigens
Community-Acquired Infections - prevention & control
Community-acquired pneumonia
Disease prevention
Double-Blind Method
Endpoint Determination
Female
Humans
Hypotheses
Immunization
Invasive pneumococcal disease
Male
Older people
PCV13
Pneumococcal conjugate vaccine
Pneumococcal Vaccines - administration & dosage
Pneumococcal Vaccines - immunology
Pneumonia
Pneumonia, Pneumococcal - prevention & control
Population
Serogroup
Streptococcus infections
Streptococcus pneumoniae
Vaccine efficacy
Vaccine Potency
Vaccines
Vaccines, Conjugate - administration & dosage
Vaccines, Conjugate - immunology
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Highlights • The 23 remaining exploratory endpoints of CAPiTA are reported. • PCV13 efficacy was 28.9–75.0% and was significant for 8 exploratory endpoints. • Significant efficacy included all confirmed pneumococcal CAP and IPD episodes. • VT serotype 1 and 7F was most common among PCV13 and placebo vaccinees, respectively. • Findings support primary CAPiTA analysis showing PCV13 prevented VT-CAP and VT-IPD.
ISSN:0264-410X
1873-2518
DOI:10.1016/j.vaccine.2017.01.032